DrugRisk Update: New Pradaxa Lawsuits Rise By 50% Amid New Bleeding Warning

The DrugRisk Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
pradaxa lawsuit
Anyone affected by internal bleeding after taking Pradaxa is urged to speak with a lawyer about their legal options as soon as possible.

Denver, CO (PRWEB) March 07, 2013

The drug safety advocates at DrugRisk.com are alerting those patients who have taken the blood thinner Pradaxa for their atrial fibrillation of new information on the site showing the number of claims over internal bleeding has risen substantially in recent months. Also, the resource center learned of a new study which concludes Pradaxa may have higher fatality rates than warfarin.

“The goal of DrugRisk is to improve drug safety by providing consumers with the latest drug warnings, recalls, studies and legal news. Informed patients can discuss treatment options with their doctor and decide if they need legal advice,“ explains DrugRisk representative Ryan Mayer.

The resource center contains information showing health experts disagree about the risk for Pradaxa internal bleeding. The FDA has updated advisories to indicate the drug carries the same risks as warfarin.* However, the American College of Cardiology has cautioned that Pradaxa can increase the risk of bleeding complications compared to warfarin.**

DrugRisk has also added a report from the Institute for Safe Medication Practices, which ranks blood thinners like Pradaxa among the most dangerous drugs. The institute reviewed nearly 18,000 adverse events reported to the FDA, and discovered patients with Pradaxa-related bleeding were nearly 5 times as likely to die than those with warfarin bleeding.***

Now, updated information from the federal judicial panel on multi-district litigation shows the number of lawsuits filed by patients alleging serious or fatal internal bleeding has grown from 170 on January 14 to 260 as of March 5, 2013, an increase of over 50%.****

Due to the number of patients filing a Pradaxa lawsuit over bleeding side effects, the cases have been consolidated to a special federal court in Illinois, formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

Anyone affected by internal bleeding after taking Pradaxa is urged to speak with a lawyer about their legal options as soon as possible. Due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who are already handling Pradaxa lawsuits.

For more information on the research, Pradaxa side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*fda.gov/Drugs/DrugSafety/ucm326580.htm
** http://content.onlinejacc.org/article.aspx?articleid=1206384
***Instutute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
****jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_by_District-March-5-2013.pdf


Contact